KV Pharmaceutical has snapped up a specialist coatings firm that it hopes will enhance the company's drug delivery product pipeline.
KV has acquired all the technologies, assets and related intellectual property of Particle and Coating Technologies (PCT), which it hopes to apply to its range of branded and generic products.
PCT uses a number of proprietary processes to deliver a variety of tableting and dosing properties to be applied in pharmaceutical products.
For example, PCT technologies can provide taste-masking for suspensions, tablets and inhalables, enhanced bioavailability, fast-chewable and -dispersable tablets, dry stable vaccines and buccal delivery of drugs.
The company also has expertise in manufacturing areas such as spray-drying, microencapsulation, atomisation and materials coating, and specific know-how in formation of nano- and microparticles, and spray-drying of unstable materials .
While the firm's technologies can be applied to other industries such as nutritional, cosmetic and veterinary sectors, PCT has applied its expertise to a number of pharmaceutical products. The company has applied its taste-masking technology to drugs for schizophrenia, incontinence and antibiotics, as well as developing 'self-boosting' vaccines, anti-inflammatory drugs and analgesics.
The firm has invested over $20m in perfecting its technologies, and has worked with clients all over the world, as well as assisting with the scaling-up of manufacturing plants for clients employing PCT technologies.
"We believe that PCT will advance the depth and breadth of KV's already formidable drug delivery expertise, as well as provide immediate benefit to multiple product opportunities currently under development at KV," said KV CEO Marc Hermelin.
Financial details of the acquisition were not disclosed.